THERAPEUTIC SEGMENT:

Lipid Lowering agent

INDICATIONS:

Lochol-EZ is a combination of ezetimibe, a dietary cholesterol absorption inhibitor, and atorvastatin, an HMG-CoA reductase inhibitor (statin) indicated:

• As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL C)

1. in adult patients with primary hyperlipidemia.
2. in adults with heterozygous familial hypercholesterolemia (HeFH).

• As an adjunct to other lipid-lowering therapies, or alone if such treatments are unavailable, to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).

BRIEF DESCRIPTION:

Lochol – EZ  contains atorvastatin and ezetimibe, two lipid-lowering compounds with complementary mechanisms of action.

Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles. Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.

DOSAGE FORM:

Tablets

10mg+10mg,

20mg+10mg

40mg+10mg